2024
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1051-1069. PMID: 38973731, DOI: 10.1002/acr.25348.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care & Research 2024, 76: 1070-1082. PMID: 38973729, DOI: 10.1002/acr.25347.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1201-1213. PMID: 38973714, DOI: 10.1002/art.42860.Peer-Reviewed Original ResearchSystemic autoimmune rheumatic diseasesInterstitial lung diseasePulmonary function testsAutoimmune rheumatic diseasesMonitoring of interstitial lung diseaseChest radiographyHigh-resolution computed tomography of the chestInterstitial lung disease risk factorsLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeDevelopment of interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansHigh-resolution computed tomographyMonitoring interstitial lung diseasesSurgical lung biopsyIdiopathic inflammatory myopathiesConnective tissue diseaseClinical practice guidelinesWalk test distanceGrading of RecommendationsEvidence-based recommendationsLung biopsy2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases
Johnson S, Bernstein E, Bolster M, Chung J, Danoff S, George M, Khanna D, Guyatt G, Mirza R, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin D, Dellaripa P, Domsic R, Doyle T, Falardeau C, Frech T, Gibbons F, Hinchcliff M, Johnson C, Kanne J, Kim J, Lim S, Matson S, McMahan Z, Merck S, Nesbitt K, Scholand M, Shapiro L, Sharkey C, Summer R, Varga J, Warrier A, Agarwal S, Antin‐Ozerkis D, Bemiss B, Chowdhary V, D'Amico J, Hallowell R, Hinze A, Injean P, Jiwrajka N, Joerns E, Lee J, Makol A, McDermott G, Natalini J, Oldham J, Saygin D, Lakin K, Singh N, Solomon J, Sparks J, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & Rheumatology 2024, 76: 1182-1200. PMID: 38978310, DOI: 10.1002/art.42861.Peer-Reviewed Original ResearchTreatment of interstitial lung diseaseSystemic autoimmune rheumatic diseasesInterstitial lung diseaseAutoimmune rheumatic diseasesLung diseaseChest PhysiciansInterstitial lung disease progressionAmerican CollegeProgressive interstitial lung diseaseRheumatic diseasesAmerican College of Chest PhysiciansClinical practice guidelinesGrading of RecommendationsEvidence-based recommendationsClinically relevant populationOutcome questionsPractice guidelinesSystematic literature reviewDiseasePhysiciansTreatmentGlucocorticoidTherapyRelevant populationRecommendations
2023
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold A, Kuwana M, Merkel P, Stock C, Sambevski S, Denton C, Bergna M, Casado G, Walter P, Proudman S, Stevens W, Thakkar V, Troy L, Loeffler-Ragg J, Olschewski H, André B, Bondue B, Houssiau F, Smith V, Wuyts W, Azevedo V, Johnson S, Keystone E, Khalidi N, Levesque M, Rozas R, Orellana A, Huang C, Li J, Jiang Z, Liu Y, Xiao W, Xu J, Zeng X, Zheng Y, Zou H, Becvar R, Madsen H, Søndergaard K, Kilpeläinen M, Myllärniemi M, Agard C, Allanore Y, Bourdin A, Cottin V, Crestani B, Diot E, Dominique S, Hachulla E, Jouneau S, Leroy S, Nunes H, Prevot G, Wallaert B, Wemeau L, Aringer M, Bewig B, Blaas S, Distler J, Ehrchen J, Ewert R, Gläser S, Henes J, Hunzelmann N, König R, Kötter I, Kreuter M, Prasse A, Schulze-Koops H, Sfikakis P, Vlachoyiannopoulos P, Losonczy G, Behera D, Devi H, Kadel J, Kawedia M, Kumar D, Kumar U, Lokhande R, Malpani A, Mohan M, Nalawade A, Parakh U, Swarnakar R, Shobha V, Thangakunam B, Udwadia Z, Henry M, O'Reilly K, Balbir-Gurman A, Kramer M, Litinsky I, Rosner I, Cutolo M, Gabrielli A, Iaccarino L, Pesci A, Riccieri V, Vettori S, Funakubo Y, Inoue Y, Kawakami A, Kawaguchi Y, Kawamura T, Kondoh Y, Kuwana M, Nanki T, Nishioka Y, Nozawa K, Ogura T, Okamoto M, Sano H, Sasai R, Sasaki N, Suda T, Takahashi H, Takeuchi T, Makino S, Tanaka S, Yamasaki Y, Ch'ng S, Cheah C, Kan S, Mohamed R, Selman M, de Vries-Bouwstra J, van den Toorn L, Vonk M, Voskuyl A, Hoffmann-Vold A, Seip M, Dankiewicz-Fares I, Olesiejuk R, Pulka G, Szepietowski J, Alves J, Bernardes M, Cordeiro A, Costa J, Neves S, Salvador M, Sancho J, Delgado P, Barranco I, Martínez J, del Castillo A, Ovalles J, López-Longo F, Gallego A, Dapena M, Ivorra J, Ekwall A, Maurer B, Mihai C, Müller R, Mahakkanukrauh A, Nantiruj K, Siripaitoon B, Denton C, Herrick A, Madhok R, Maher T, West A, Antin-Ozerkis D, Bascom R, Criner G, Csuka M, D'Amico J, Ettinger N, Fischer A, Gerbino A, Gerke A, Glassberg M, Glazer C, Golden J, Gripaldo R, Gupta N, Hamblin M, Highland K, Ho L, Huggins J, Hummers L, Jones L, Kahaleh M, Khanna D, Kim H, Lancaster L, Luckhardt T, Mayes M, Ballesteros F, Mooney J, Mohabir P, Morrissey B, Moua T, Padilla M, Patel N, Perez R, Roman J, Rossman M, Russell T, Saketkoo L, Shah A, Shlobin O, Scholand M, Simms R, Spiera R, Steen V, Veeraraghavan S, Weigt S. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology 2023, 63: 639-647. PMID: 37294870, PMCID: PMC10907814, DOI: 10.1093/rheumatology/kead280.Peer-Reviewed Original ResearchLimited cutaneous systemic sclerosisInterstitial lung diseaseCutaneous systemic sclerosisSENSCIS trialEffect of nintedanibWeek 52Nintedanib groupPlacebo groupSystemic sclerosisLung diseaseProgressive fibrosing interstitial lung diseasesOpen-label nintedanibSSc-ILDLung functionPulmonary fibrosisNintedanibPatientsRate of declineFVCTrialsPlaceboSclerosisDiseaseGroupFibrosis
2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells A, Flaherty K, Brown K, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts W, Stowasser S, Quaresma M, Goeldner R, Schlenker-Herceg R, Kolb M, investigators I, Abe S, Aburto M, Acosta O, Andrews C, Antin-Ozerkis D, Arce G, Arias M, Avdeev S, Barczyk A, Bascom R, Bazdyrev E, Beirne P, Belloli E, Bergna M, Bergot E, Bhatt N, Blaas S, Bondue B, Bonella F, Britt E, Buch K, Burk J, Cai H, Cantin A, Villegas D, Cazaux A, Cerri S, Chaaban S, Chaudhuri N, Cottin V, Crestani B, Criner G, Dahlqvist C, Danoff S, D'Amico J, Dilling D, Elias P, Ettinger N, Falk J, Pérez E, Gamez-Dubuis A, Giessel G, Gifford A, Glassberg M, Glazer C, Golden J, Carrera L, Guiot J, Hallowell R, Hayashi H, Hetzel J, Hirani N, Homik L, Hope-Gill B, Hotchkin D, Ichikado K, Ilkovich M, Inoue Y, Izumi S, Jassem E, Jones L, Jouneau S, Kaner R, Kang J, Kawamura T, Kessler R, Kim Y, Kishi K, Kitamura H, Kolb M, Kondoh Y, Kono C, Koschel D, Kreuter M, Kulkarni T, Kus J, Lebargy F, Jiménez A, Luo Q, Mageto Y, Maher T, Makino S, Marchand-Adam S, Marquette C, Martinez R, Martínez M, Rozas R, Miyazaki Y, Moiseev S, Molina-Molina M, Morrison L, Morrow L, Moua T, Nambiar A, Nishioka Y, Nunes H, Okamoto M, Oldham J, Otaola M, Padilla M, Park J, Patel N, Pesci A, Piotrowski W, Pitts L, Poonyagariyagorn H, Prasse A, Quadrelli S, Randerath W, Refini R, Reynaud-Gaubert M, Riviere F, Portal J, Rosas I, Rossman M, Safdar Z, Saito T, Sakamoto N, Fénero M, Sauleda J, Schmidt S, Scholand M, Schwartz M, Shapera S, Shlobin O, Sigal B, Orellana A, Skowasch D, Song J, Stieglitz S, Stone H, Strek M, Suda T, Sugiura H, Takahashi H, Takaya H, Takeuchi T, Thavarajah K, Tolle L, Tomassetti S, Tomii K, Valenzuela C, Vancheri C, Varone F, Veeraraghavan S, Villar A, Weigt S, Wemeau L, Wuyts W, Xu Z, Yakusevich V, Yamada Y, Yamauchi H, Ziora D. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine 2020, 8: 453-460. PMID: 32145830, DOI: 10.1016/s2213-2600(20)30036-9.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseIdiopathic pulmonary fibrosisIdiopathic non-specific interstitial pneumoniaAutoimmune interstitial lung diseaseUnclassifiable idiopathic interstitial pneumoniaNon-specific interstitial pneumoniaDose of nintedanibParallel-group trialIdiopathic interstitial pneumoniaEffect of nintedanibINBUILD trialInterstitial pneumoniaILD diagnosisHigh-resolution CTILD progressionFVC declineHypersensitivity pneumonitisProgressive fibrosing interstitial lung diseasesOverall populationInterstitial lung disease diagnosisChest imaging featuresProtocol-defined criteriaSafety of nintedanibChronic hypersensitivity pneumonitisDisease subgroup analyses
2019
Connective Tissue Disease–Associated Interstitial Lung Disease Evaluation and Management
Antin-Ozerkis D, Hinchcliff M. Connective Tissue Disease–Associated Interstitial Lung Disease Evaluation and Management. Clinics In Chest Medicine 2019, 40: 617-636. PMID: 31376896, DOI: 10.1016/j.ccm.2019.05.008.Peer-Reviewed Original ResearchConceptsNonpharmacologic management strategiesMainstay of therapyConnective tissue diseaseInterstitial lung diseaseRate of progressionDisease activityTherapy initiationTissue diseaseRadiographic findingsLung diseaseDrug toxicityDisease severityDisease evaluationMultidisciplinary approachPatientsDiseaseImportant contributorImmunosuppressionMorbidityTherapyInfectionMainstayMortalityProgressionTrialsSerious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials
Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vašáková M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB. Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respiratory Medicine 2019, 150: 120-125. PMID: 30961937, DOI: 10.1016/j.rmed.2019.02.021.Peer-Reviewed Original ResearchConceptsSerious adverse eventsIdiopathic pulmonary fibrosisAdverse eventsPulmonary fibrosisClinical trialsCardiac disordersFatal interstitial lung diseaseInterstitial lung diseaseRespiratory failureCommon comorbiditiesPlacebo armLung functionFatal outcomeLung diseasePooled analysisMyocardial infarctionUnpredictable courseDisease progressionFatal infectionSafety dataPatientsPlaceboFibrosisInfectionTrials
2018
Chapter 13 Interstitial Lung Disease in the Connective Tissue Diseases
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer R, Matthay R. Chapter 13 Interstitial Lung Disease in the Connective Tissue Diseases. 2018, 157-185. DOI: 10.1016/b978-0-323-48024-6.00013-6.Peer-Reviewed Original ResearchConnective tissue diseaseInterstitial lung diseaseCTD-ILDTissue diseaseLung diseaseIdiopathic interstitial lung diseaseFulminant respiratory failureRespiratory failureImmunosuppressive agentsHealthy patientsDrug reactionsFirst manifestationGradual onsetDiagnostic approachDiseaseCareful searchCommon formSubtle evidenceTreatmentDyspneaCorticosteroidsCoughPatientsInfectionDiagnosis
2014
Supportive Care for Patients with Pulmonary Complications of Connective Tissue Disease
Gulati M, Antin-Ozerkis D. Supportive Care for Patients with Pulmonary Complications of Connective Tissue Disease. Seminars In Respiratory And Critical Care Medicine 2014, 35: 274-282. PMID: 24668542, DOI: 10.1055/s-0034-1371538.Peer-Reviewed Original ResearchConceptsConnective tissue diseaseQuality of lifePulmonary complicationsSupportive careTissue diseaseLung diseaseAdvanced lung diseaseGastroesophageal reflux diseaseGlucocorticoid-induced osteoporosisInterstitial lung diseaseManagement of patientsLung transplantationTreatable comorbiditiesPulmonary hypertensionPulmonary rehabilitationReflux diseaseSignificant comorbiditiesMechanical ventilationPatient's symptomsSupplemental oxygenPulmonary disordersSleep disturbancesCardiovascular diseaseMood disordersSupportive measures
2013
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
Saketkoo L, Mittoo S, Huscher D, Khanna D, Dellaripa P, Distler O, Flaherty K, Frankel S, Oddis C, Denton C, Fischer A, Kowal-Bielecka O, LeSage D, Merkel P, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman R, Castelino F, Christmann R, Christopher-Stine L, Collard H, Cottin V, Danoff S, Highland K, Hummers L, Shah A, Kim D, Lynch D, Miller F, Proudman S, Richeldi L, Ryu J, Sandorfi N, Sarver C, Wells A, Strand V, Matteson E, Brown K, Seibold J, Aggarwal* R, Ainslie G, Alkassab F, Allanore Y, Descartes P, Anderson M, Andonopoulos A, Antin-Ozerkis D, Arrobas A, Ascherman* D, Assassi S, Baron M, Bathon* J, Behr J, Beretta L, Bingham C, Binnie M, Birring S, Boin F, Bongartz* T, Bourdin A, Bouros D, Brasington R, Bresser P, Buch M, Burge P, Carmona L, Carreira P, Carvalho C, Catoggio L, Chan K, Chapman J, Chatterjee S, Chua* F, Chung L, Conron M, Corte T, Cosgrove G, Costabel U, Cox G, Crestani B, Crofford L, Csuka M, Curbelo P, László C, Daniil Z, D'Arsigny C, Davis G, de Andrade J, De Vuyst P, Dempsey O, Derk C, Distler J, Dixon* W, Downey G, Doyle M, Drent M, Durairaj L, Emery P, Espinoza L, Farge D, Fathi M, Fell C, Fessler B, Fitzgerald J, Fox G, Foeldvari I, Frech T, Freitas S, Furst* D, Gabrielli A, García-Vicuña R, Georgiev O, Gerbino A, Gillisen A, Gladman D, Glassberg M, Gochuico B, Gogali A, Goh* N, Goldberg A, Goldberg H, Gourley* M, Griffing L, Grutters J, Gunnarsson R, Hachulla E, Hall F, Harari S, Herrick A, Herzog E, Hesselstrand R, Hirani N, Hodgson U, Hollingsworth H, Homer R, Hoyles R, Hsu V, Hubbard R, Hunzelmann N, Isasi M, Isasi E, Jimenez J, Johnson S, Jones C, Kahaleh B, Kairalla R, Kalluri M, Kalra S, Kaner R, Kinder B, Klingsberg R, Kokosi M, Kolb M, Kur-Zalewska J, Kuwana* M, Lake F, Lally E, Lasky J, Laurindo I, Able L, Lee P, Leonard C, Lien D, Limper A, Liossis S, Lohr K, Loyd J, Lundberg* I, Mageto Y, Maher T, Mahmud T, Manganas H, Marie I, Marras T, Martinez J, Martinez F, Mathieu A, Matucci-Cerinic* M, Mayes* M, McKown K, Medsger T, Meehan R, Cristina M, Meyer K, Millar A, Moğulkoç N, Molitor J, Morais A, Mouthon P, Müller V, Müller-Quernheim J, Nadashkevich O, Nador R, Nash P, Nathan S, Navarro C, Neves S, Noth I, Nunes H, Olson A, Opitz C, Padilla M, Pappas D, Parfrey H, Pego-Reigosa J, Pereira C, Perez R, Pope* J, Porter J, Renzoni E, Riemekasten G, Riley D, Rischmueller M, Rodriguez-Reyna T, Rojas-Serrano, Romam J, Rosen G, Rossman M, Rothfield N, Sahn S, Sanduzzi A, Scholand M, Selman M, Senécal J, Seo P, Silver* R, Solomon J, Steen* V, Stevens W, Strange C, Sussman R, Sutton E, Sweiss N, Tornling G, Tzelepis G, Undurraga A, Vacca A, Vancheri C, Varga J, Veale D, Volkov S, Walker U, Wencel M, Wesselius L, Wickremasinghe M, Wilcox P, Wilsher M, Wollheim F, Wuyts W, Yung G, Zanon P, Zappala C, Groshong S, Leslie K, Myers J, Padera R, Desai S, Goldin J, Kazerooni E, Klein J, Lynch D, Keen K. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2013, 69: 436. PMID: 24368713, PMCID: PMC3995282, DOI: 10.1136/thoraxjnl-2013-204202.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisConnective tissue diseaseInterstitial lung diseaseCTD-ILDPulmonary fibrosisTissue diseaseLung diseaseClinical trialsOutcome measuresRelated interstitial lung diseaseNominal group panelHealth-related qualityPatient focus groupsMulticentre clinical trialAppropriate outcome measuresClinical trial designILD expertsDisease activityMulticentre RCTsTreatment responseLung physiologyTrial designConsensus methodologyIdentification of outcomesLung imaging
2012
Interstitial Lung Disease in the Connective Tissue Diseases
Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial Lung Disease in the Connective Tissue Diseases. Clinics In Chest Medicine 2012, 33: 123-149. PMID: 22365251, DOI: 10.1016/j.ccm.2012.01.004.Peer-Reviewed Original ResearchConceptsConnective tissue diseaseInterstitial lung diseaseLung diseaseTissue diseaseIdiopathic interstitial lung diseaseFulminant respiratory failureCTD-ILDRespiratory failureImmunosuppressive agentsHealthy patientsDrug reactionsFirst manifestationGradual onsetDiseaseCareful searchSubtle evidenceDyspneaCorticosteroidsCoughPatientsInfectionDiagnosis
2011
Interstitial Lung Disease in Older Patients
Antin-Ozerkis D. Interstitial Lung Disease in Older Patients. Respiratory Medicine 2011, 201-226. DOI: 10.1007/978-1-60761-727-3_11.Peer-Reviewed Original ResearchInterstitial lung diseaseDiffuse parenchymal lung diseaseLung diseaseOlder patientsRespiratory statusTerm interstitial lung diseasePatient's respiratory statusParenchymal lung diseaseDetailed physical examinationYounger patientsPathologic featuresCareful historyPhysical examinationLung disordersMedical conditionsSpecific diagnosisPhysiologic studiesDiagnostic approachMultidisciplinary conferenceDiseasePatientsPathologic tissueHeterogeneous groupLaboratory dataCertain diseases
2010
Pulmonary Manifestations of Rheumatoid Arthritis
Antin-Ozerkis D, Evans J, Rubinowitz A, Homer RJ, Matthay RA. Pulmonary Manifestations of Rheumatoid Arthritis. Clinics In Chest Medicine 2010, 31: 451-478. PMID: 20692539, DOI: 10.1016/j.ccm.2010.04.003.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisPulmonary diseaseLung diseaseInterstitial lung diseaseUse of drugsPulmonary manifestationsAirway diseaseRheumatoid nodulesPleural effusionRespiratory abnormalitiesPulmonary toxicityArthritisDiseaseDiagnostic assessmentMultidisciplinary approachMorbidityEffusionInfectionMortalityAbnormalitiesCirculating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype
Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Investigation 2010, 90: 812-823. PMID: 20404807, PMCID: PMC3682419, DOI: 10.1038/labinvest.2010.73.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseSSc-ILD patientsSSc-ILDIL-10Normal controlsProfibrotic cellsSystemic sclerosisLung diseaseCollagen-producing cellsMCP-1Profibrotic phenotypeSSc-related interstitial lung diseaseFlow cytometryPeripheral blood profilesSSc-ILD cohortsIL-10 secretionSystemic sclerosis patientsExpression of CD163Blood of patientsHealthy aged controlsCultured CD14Profibrotic characteristicsProfibrotic mediatorsTNF levelsSclerosis patients